Thus, the eEF2/eEF2K pathway may be an alluring target for novel pharmacological interventions for AD, but the level to which eEF2K is inhibited to produce a therapeutic effect will need to be further explored. The gene discussed is EEF2K; the disease is Alzheimer disease.